Development of M5 Selective Muscarinic Antagonists

MS muscarinic acetylcholine receptors (mAChRs) have emerged as a potential target for the treatment of drug abuse, based on brain region localization, involvement in the regulation of central dopaminergic pathways, and behavioral data from MSknockout mice. However, the exact physiological role of this receptor and its potential for pharmacotherapeutic development are ambiguous due to the lack of selective ligands. The purpose of the current proposal is to develop novel MS receptor antagonists. Based on a reported nonselective muscarinic antagonist, we generated over 70 structurally-related analogs using a progressive step-by-step structural modification strategy from which several new leads with increased selectivity and potency for MS mAChR subtypes have been identified. Druggable virtual hits will be synthesized by Dr. Zheng and evaluated in receptor binding assays using CHO cells expressing hM1-hMS. Analogs selective for MS will be evaluated in functional assays using native MS receptors and lead analogs will be evaluated also in off-target assays, for in vitro cardiotoxicity (hERG assays) and neurotoxicity (dopamine striatal content). We anticipate the discovery of promising MS antagonists, which will be useful pharmacological tools and have potential as novel therapeutic agents for the treatment of drug abuse.